Prof John Wagstaff -- University of Swansea, Wales
Prof Wagstaff speaks about his highlights from the 2010 ASCO conference. These include the extremely positive results of a trial investigating ipilimumab. This monocolonal antibody modulates the immune system, activating a T-cell response which helps the body fight metastatic melanoma. A number of trials have produced encouraging results, however, ipilimumab is associated with some severe side effects. Prof Wagstaff speaks about BRAF inhibitors and their role in cancer treatment.
Link to this comment:
All Comments (0)